These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The Past, Present, and Future of Dual-Antiplatelet Therapy Duration in Percutaneous Coronary Intervention. Abbott JD Ann Intern Med; 2017 Jul; 167(1):57-58. PubMed ID: 28605778 [No Abstract] [Full Text] [Related]
9. Still a Long Way to the Precision Medicine of Antiplatelet Strategy After Percutaneous Coronary Intervention. Jeong YH; Obayashi Y; Song H; Kimura T Circ Cardiovasc Interv; 2022 Aug; 15(8):e012261. PubMed ID: 35899617 [No Abstract] [Full Text] [Related]
10. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Sibbing D; Aradi D; Alexopoulos D; Ten Berg J; Bhatt DL; Bonello L; Collet JP; Cuisset T; Franchi F; Gross L; Gurbel P; Jeong YH; Mehran R; Moliterno DJ; Neumann FJ; Pereira NL; Price MJ; Sabatine MS; So DYF; Stone GW; Storey RF; Tantry U; Trenk D; Valgimigli M; Waksman R; Angiolillo DJ JACC Cardiovasc Interv; 2019 Aug; 12(16):1521-1537. PubMed ID: 31202949 [TBL] [Abstract][Full Text] [Related]
11. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104 [TBL] [Abstract][Full Text] [Related]
12. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH; Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581 [TBL] [Abstract][Full Text] [Related]
13. Perceived or Calculated Bleeding Risk and Their Relation With Dual Antiplatelet Therapy Duration in Patients Undergoing Percutaneous Coronary Intervention. Ferlini M; Rossini R; Musumeci G; Grieco N; Demarchi A; Trabattoni D; Zavalloni Parenti D; Pierini S; Castiglioni B; Somaschini A; Cornara S; Lettieri C; Oltrona Visconti L Circ Cardiovasc Interv; 2019 Jun; 12(6):e007949. PubMed ID: 31142150 [No Abstract] [Full Text] [Related]
14. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial. Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191 [TBL] [Abstract][Full Text] [Related]